Frontiers in Immunology (May 2025)
Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis
- Wei Ren,
- Hanyu Zhang,
- Yixin Li,
- Wu Sun,
- Hexiang Peng,
- Huangda Guo,
- Tianjiao Hou,
- Mengying Wang,
- Mengying Wang,
- Zhendong Hu,
- Tao Wu,
- Tao Wu,
- Baorui Liu
Affiliations
- Wei Ren
- The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China
- Hanyu Zhang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Yixin Li
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Wu Sun
- The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China
- Hexiang Peng
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Huangda Guo
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Tianjiao Hou
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Mengying Wang
- Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China
- Mengying Wang
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China
- Zhendong Hu
- Department of Esophageal Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
- Tao Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Tao Wu
- Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China
- Baorui Liu
- The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China
- DOI
- https://doi.org/10.3389/fimmu.2025.1611591
- Journal volume & issue
-
Vol. 16
Abstract
No abstracts available.Keywords
- PD-1/PD-L1 inhibitor
- esophageal squamous cell carcinoma
- meta-analysis
- immunotherapy
- combined positive score
